
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).






